Haleon has been a hotspot with a flurry of activities. The company's
CEO Brian McNamara sold 704,974 shares, alongside sell-off to meet tax liabilities brought about by share vesting. The sale seemingly coincides with Haleon's implementation of an ongoing
buyback initiative that has seen millions of shares cancelled.
The company's growth narrative seems promising with its 3% organic growth in 2025 boosted by the 'Win as One' strategy. It also made notable investments including a £65m for a toothpaste plant in China and plans to usher in a turning point with its
Consumer-Health Story in 2026.
Barclays has upgraded Haleon's stock rating to Overweight, reflecting an improving US outlook. There is noteworthy buying and selling activity with different entities purchasing and others, like Dodge & Cox, offloading Haleon's shares. The firm's intrinsic value is potentially 76% above the current share price and the firm has issued
2026 Performance and Bonus share awards to CEO and CFO.
Despite mixed reviews amid revenue growth falling short of the company's own medium-term target, the market trends are favorable. However, weaknesses in the US market look to impact 2026 sales causing Haleon's stock to struggle. Yet, Haleon's cost savings and efficiency gains are positive signs.
Cautious 2026 guidance following a Q4 sales miss and
share buyback program led the company's share to fall.
Haleon Stocks News Analytics from Thu, 01 May 2025 07:00:00 GMT to Fri, 27 Mar 2026 07:25:09 GMT -
Rating 2
- Innovation 6
- Information 5
- Rumor -4
